Results 51 to 60 of about 484,531 (179)

Cardiovascular pharmacology of thyrotropin releasing hormone [PDF]

Peptides, 1988
Thyrotropin releasing hormone (TRH) and its receptors are present in the cardiovascular nuclei of the brain as well as in the intermediolateral cell column of spinal cord. Anatomical, neurophysiological, functional and pharmacological studies suggest that TRH is a neurotransmitter/neuromodulator in the central nervous system.
openaire   +2 more sources

Mass Spectrometry Insights Into Post‐Translational Modifications in Extracellular Vesicles

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐enclosed structures secreted by virtually all living cells, serving as essential mediators of intercellular communication in both physiological and pathological processes. There is growing interest in their potential applications as biomarkers, therapeutic targets, and drug delivery systems, which ...
Dávid Virág, Krisztián Márk Karvaly, Alexandra Molnár, Mirjam Balbisi, Júlia Németh, Lilla Turiák   +5 more
wiley   +1 more source

Brain Delivery of Thyrotropin-Releasing Hormone via a Novel Prodrug Approach

Pharmaceutics, 2019
Using thyrotropin-releasing hormone (TRH) as a model, we explored whether synergistic combination of lipoamino acid(s) and a linker cleaved by prolyl oligopeptidase (POP) can be used as a promoiety for prodrug design for the preferential brain delivery ...
Katalin Prokai-Tatrai, Daniel L. De La Cruz, Vien Nguyen, Benjamin P. Ross, Istvan Toth, Laszlo Prokai   +5 more
doaj   +1 more source

The Diagnostic Performance of Afirma Genomic Sequencing Classifier in Black and Hispanic Patients With Indeterminate Thyroid Nodules

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective About 20% of thyroid nodules detected on ultrasound are cytologically indeterminate (Bethesda categories III and IV), but the rate of malignancy of these nodules is less than 36%. The ability of Afirma Genomic Sequencing Classifier (GSC) to further risk‐stratify indeterminate thyroid nodules among Black and Hispanic patients is ...
Peter J. Attia, Sree Chinta, Joseph Celidonio, John Sebastian De Armas, Evelyne Kalyoussef, Dylan F. Roden   +5 more
wiley   +1 more source

Effect of Ghrelin and Thyrotropin-releasing Hormone on Prolactin Secretion in Normal Women

, 2010
It is known that ghrelin stimulates the secretion of prolactin in women. The aim of this study was to examine the effect of exogenous thyrotropin-releasing hormone (TRH) on ghrelin-induced prolactin release.
Georgoulias, P., Messini, C. I., Dafopoulos, K., Anifandis, G., Messinis, I. E., Chalvatzas, N.   +5 more
core   +1 more source

Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor

Frontiers in Endocrinology, 2012
Taltirelin (TAL) is a thyrotropin-releasing hormone (TRH) analog that is approved for use in humans in Japan. In this study, we characterized TAL binding to and signaling by the human TRH receptor (TRH-R) in a model cell system.
Nanthakumar eThirunarayanan, Bruce M. Raaka, Marvin C Gershengorn   +2 more
doaj   +1 more source

Thyrotropinoma - the case report about one of the rarest type of pituitary adenomas

Journal of Education, Health and Sport, 2022
Pituitary tumours are a significant diagnostic problem in clinical practice. Considering all the rarity of thyrotropic hormone secreting adenoma it is a diagnostic and therapeutic challenge in part due to the lack of the preoperative standards. TSH-oma,
Piotr Michał Jarosz, Zuzanna Idzik, Jakub Gołacki, Ewa Obel   +3 more
doaj   +1 more source

Herbal Therapeutics in Osteoporosis: Mechanisms, Evidence, and Translational Potential

Phytotherapy Research, EarlyView.
Schematic overview of bone remodeling dysregulation in osteoporosis and the multi‐target protective role of herbal therapeutics. ABSTRACT Osteoporosis is a chronic bone disease marked by reduced density and increased fracture risk. Current treatments face limitations in safety, efficacy, and long‐term adherence, prompting interest in alternative ...
Elnaz Vafadar Moradi, Sina Vossoughinia, Zahra Yazdanpanah, Hossein Sobhani, Jalileh Jalali, Mahboobeh Ghasemzadeh Rahbardar   +5 more
wiley   +1 more source

Investigation of Responsiveness to Thyrotropin-Releasing Hormone in Growth Hormone-Producing Pituitary Adenomas

International Journal of Endocrinology, 2013
Objective. The aim of this study was to investigate how the paradoxical response of GH secretion to TRH changes according to tumor volumes. Methods.
Sang Ouk Chin, Sang Youl Rhee, Suk Chon, You-Cheol Hwang, In-Kyung Jeong, Seungjoon Oh, Sung-Woon Kim   +6 more
doaj   +1 more source

Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses

Journal of Veterinary Internal Medicine, 2021
Background Diagnosis of pituitary pars intermedia dysfunction (PPID) is problematic because of large variations in ACTH concentrations. Hypothesis/Objectives Compare the test characteristics of baseline and post–thyrotropin‐releasing hormone (TRH ...
Remona Horn, Allison J. Stewart, Karen V. Jackson, Elizabeth L. Dryburgh, Carlos E. Medina‐Torres, François‐René Bertin   +5 more
doaj   +1 more source